Al-Ismail SA - Search Results

1

Systolic time interval to predict doxorubicin cardiotoxicity.

Al-Ismail SA, Whittaker JA. Al-Ismail SA, et al. Lancet. 1978 Jun 17;1(8077):1315. doi: 10.1016/s0140-6736(78)91304-1. Lancet. 1978. PMID: 78080 No abstract available.

2

Systolic time interval as index of schedule--dependent doxorubicin cardiotoxicity in patients with acute myelogenous leukaemia.

Al-Ismail S, Whittaker JA. Al-Ismail S, et al. Br Med J. 1979 May 26;1(6175):1392-5. doi: 10.1136/bmj.1.6175.1392. Br Med J. 1979. PMID: 286623 Free PMC article.

3

Lymphocytic lymphoma after idiopathic hypersplenism.

Al-Ismail SA, Bentley DP, Whittaker JA. Al-Ismail SA, et al. Lancet. 1977 Oct 22;2(8043):881. doi: 10.1016/s0140-6736(77)90822-4. Lancet. 1977. PMID: 72232 No abstract available.

4

Synchronisation of cell phase in treatment of leukaemia.

Whittaker JA, al-Ismail SA. Whittaker JA, et al. Lancet. 1977 Sep 10;2(8037):557. doi: 10.1016/s0140-6736(77)90687-0. Lancet. 1977. PMID: 95755 No abstract available.

5

Anthracycline cardiotoxicity and acute myelogenous leukaemia.

Al-Ismail SA, Parry DH, Whittaker JA. Al-Ismail SA, et al. Br Med J. 1977 Mar 26;1(6064):815. doi: 10.1136/bmj.1.6064.815. Br Med J. 1977. PMID: 265741 Free PMC article. No abstract available.

6

Effect of digoxin and vitamin E in preventing cardiac damage caused by doxorubicin in acute myeloid leukaemia.

Whittaker JA, Al-Ismail SA. Whittaker JA, et al. Among authors: al ismail sa. Br Med J (Clin Res Ed). 1984 Jan 28;288(6413):283-4. doi: 10.1136/bmj.288.6413.283-a. Br Med J (Clin Res Ed). 1984. PMID: 6419896 Free PMC article. Clinical Trial. No abstract available.

7

Combination chemotherapy including epirubicin for the management of non-Hodgkin's lymphoma.

Al-Ismail SA, Whittaker JA, Gough J. Al-Ismail SA, et al. Eur J Cancer Clin Oncol. 1987 Sep;23(9):1379-84. doi: 10.1016/0277-5379(87)90123-4. Eur J Cancer Clin Oncol. 1987. PMID: 3315698 Clinical Trial.

8

An assessment of laparotomy in the management of patients with Hodgkin's disease.

Whittaker JA, Slater A, Al-Ismail SA, Gough J, Evans KT, Evans IH, Crosby DL. Whittaker JA, et al. Among authors: al ismail sa. Q J Med. 1978 Jul;47(187):291-301. Q J Med. 1978. PMID: 715170

9

Erythropoiesis and iron metabolism in Hodgkin's disease.

Al-Ismail S, Cavill I, Evans IH, Jacobs A, Ricketts C, Trevett D, Whittaker JA. Al-Ismail S, et al. Br J Cancer. 1979 Sep;40(3):365-70. doi: 10.1038/bjc.1979.190. Br J Cancer. 1979. PMID: 508565 Free PMC article.

10

The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial.

Burnett AK, Milligan D, Goldstone A, Prentice A, McMullin MF, Dennis M, Sellwood E, Pallis M, Russell N, Hills RK, Wheatley K; United Kingdom National Cancer Research Institute Haematological Oncology Study Group. Burnett AK, et al. Br J Haematol. 2009 May;145(3):318-32. doi: 10.1111/j.1365-2141.2009.07604.x. Epub 2009 Mar 8. Br J Haematol. 2009. PMID: 19291085 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

35 results

Search Page

Filters